์‹ฌ์ •์ง€ ํ›„ ์‹ ๊ฒฝํ•™์  ์˜ˆํ›„ ํ‰๊ฐ€ / Post-cardiac arrest neuroprognostication

์ •์˜

ROSC ํ›„ ๋‡Œ์†์ƒ ์ •๋„์™€ ์˜ˆํ›„๋ฅผ SEP, NSE, S-100 ๋“ฑ ๋‹ค์ค‘ ์ง€ํ‘œ๋กœ ํ‰๊ฐ€ํ•˜๋Š” ๊ณผ์ •.

์ž„์ƒ ํ•ต์‹ฌ

์˜ˆํ›„ ํ‰๊ฐ€๋Š” CPR 5์ผ ํ›„, ๋˜๋Š” TTM์œผ๋กœ ์ฒด์˜จ ํšŒ๋ณต ํ›„ 3์ผ ํ›„๊ฐ€ ์–ธ๊ธ‰๋จ. ๋‹จ์ผ ๊ฒ€์‚ฌ๋งŒ์œผ๋กœ ํŒ๋‹จํ•˜์ง€ ์•Š๊ณ  multimodal approach๊ฐ€ ํ•„์š”ํ•˜๋‹ค๊ณ  ๊ธฐ๋ก๋จ. NSE๋Š” ์ž˜ ๋ณด๋Š” ์ง€ํ‘œ๋กœ ์–ธ๊ธ‰๋˜๋‚˜ ์œ„์–‘์„ฑ ์›์ธ์ด ์žˆ๋‹ค.

์ง„๋‹จ

SEP๋Š” median nerve ์ž๊ทน ํ›„ vertebral N13, cerebral N18 ์‹ ํ˜ธ์™€ ์‹œ๊ฐ„์„ ๋ณธ๋‹ค. N13 ์‹ ํ˜ธ๊ฐ€ ์—†๊ฑฐ๋‚˜ N13์€ ์žˆ์œผ๋‚˜ N18์ด ์—†์œผ๋ฉด ์˜ˆํ›„ poor๋กœ ๊ธฐ๋ก๋จ. NSE๋Š” neuron-specific enolase๋กœ ๋‡Œ์†์ƒ ์‹œ ํ˜ˆ์ค‘ ์ƒ์Šนํ•˜๋ฉฐ, >60์ด๋ฉด poor๋กœ ์–ธ๊ธ‰๋จ. S-100์€ astrocyte/glial cell ๋‹จ๋ฐฑ์œผ๋กœ ์ดˆ๊ธฐ brain injury๋ฅผ ๋ฐ˜์˜ํ•˜์ง€๋งŒ specificity๊ฐ€ NSE๋ณด๋‹ค ๋‚ฎ๋‹ค.

์น˜๋ฃŒ

์˜ˆํ›„ ํ‰๊ฐ€ ๊ฒฐ๊ณผ๋Š” ์น˜๋ฃŒ ์ค‘๋‹จ ๋‹จ๋… ๊ทผ๊ฑฐ๊ฐ€ ์•„๋‹ˆ๋ผ ์ž„์ƒ ๊ฒฝ๊ณผ, ์˜์ƒ, ์ „๊ธฐ์ƒ๋ฆฌ, biomarker๋ฅผ ํ†ตํ•ฉํ•ด ํ•ด์„ํ•œ๋‹ค. Hemolysis, small cell lung cancer, neuroendocrine tumor, renal failure๋Š” NSE ์œ„์–‘์„ฑ ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ์–ด ์ฃผ์˜ํ•œ๋‹ค.

์ถœ์ฒ˜

raw ์ž๋ฃŒ ๋‚ด ๋ณ„๋„ DOI/๊ณต์‹ ๊ฐ€์ด๋“œ๋ผ์ธ ์ธ์šฉ ์—†์Œ.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.

๐Ÿ“ ์ถ”๊ฐ€ (2026-05-12, source: 2026-05-09-1228-d2d5c418.md)

์ •์˜

Post-cardiac arrest neuroprognostication์€ ROSC ํ›„ ํ˜ผ์ˆ˜๊ฐ€ ์ง€์†๋˜๋Š” ํ™˜์ž์—์„œ poor neurologic outcome ๊ฐ€๋Šฅ์„ฑ์„ ํ‰๊ฐ€ํ•˜๋Š” ๊ณผ์ •์ด๋‹ค.

์ž„์ƒ ํ•ต์‹ฌ

์˜ˆํ›„ ํ‰๊ฐ€๋Š” ๋‹จ์ผ ๊ฒ€์‚ฌ๋‚˜ ๋‹จ์ผ biomarker๋กœ ๊ฒฐ์ •ํ•˜์ง€ ์•Š๊ณ  multimodal approach๊ฐ€ ์›์น™์ด๋‹ค. NSE๋Š” ๋ณด์กฐ ์ง€ํ‘œ์ด๋ฉฐ, 48โ€“72์‹œ๊ฐ„ ๊ณ ๊ฐ’ ๋˜๋Š” ์ƒ์Šน ์ถ”์„ธ๊ฐ€ ๋‹ค๋ฅธ ๋ถˆ๋Ÿ‰ ์˜ˆํ›„ ์†Œ๊ฒฌ๊ณผ ํ•จ๊ป˜ ์žˆ์„ ๋•Œ ์˜๋ฏธ๊ฐ€ ์ปค์ง„๋‹ค. WLST ๊ฒฐ์ •์€ NSE ๋‹จ๋… ๊ฒฐ๊ณผ๋งŒ์œผ๋กœ ๋‚ด๋ ค์„œ๋Š” ์•ˆ ๋œ๋‹ค.

์ง„๋‹จ

ํ‰๊ฐ€ ์š”์†Œ์—๋Š” neurologic exam, pupillary/corneal reflex, EEG, SSEP N20, brain CT/MRI, myoclonus, NSE ๋“ฑ์ด ํฌํ•จ๋œ๋‹ค. ROSC ํ›„ 24, 48, 72์‹œ๊ฐ„ serial NSE ์ธก์ •์ด ํ”ํžˆ ์‚ฌ์šฉ๋œ๋‹ค. ERC/ESICM 2021์—์„œ๋Š” NSE >60 ยตg/L at 48 h and/or 72 h๋ฅผ ๋ถˆ๋Ÿ‰ ์˜ˆํ›„ ์˜ˆ์ธก ์ธ์ž ์ค‘ ํ•˜๋‚˜๋กœ ์ œ์‹œํ•œ๋‹ค.

์น˜๋ฃŒ

์˜ˆํ›„ํ‰๊ฐ€๋Š” ๋ณดํ†ต normothermia ํšŒ๋ณต ํ›„, sedation/paralytic/metabolic confounder๋ฅผ ์ œ๊ฑฐํ•˜๊ณ  72์‹œ๊ฐ„ ์ดํ›„ ์‹œํ–‰ํ•˜๋Š” ๊ฒƒ์ด ์›์น™์ด๋‹ค. ์น˜๋ฃŒ ๋ฐฉํ–ฅ๊ณผ WLST ํŒ๋‹จ์€ ๋‹ค์ค‘์–‘์‹ ํ‰๊ฐ€ ๊ฒฐ๊ณผ๋ฅผ ์ข…ํ•ฉํ•ด ๊ฒฐ์ •ํ•œ๋‹ค.

์ถœ์ฒ˜